Navigation

Arthritis (juvenile idiopathic, systemic) - tocilizumab

Tocilizumab for juvenile idiopathic arthritis

Status: History
Expected date of issue: December 2011
Referral date: June 2007
Process: STA
Topic area:
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Alfred Sackeyfio
Communications manager: Tonya Gillis
Project manager: Lori Farrar
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 5 April 2011
1st appraisal committee meeting: 13 July 2011
2nd appraisal committee meeting 14 September 2011
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Roche Products  (tocilizumab)

Patient/carer groups

  • Arthritis Care
  • National Rheumatoid Arthritis Society
  • South Asian Health Foundation

Professional groups

  • British Health Professionals in Rheumatology
  • British Society for Paediatric and Adolescent Rheumatology
  • British Society for Rheumatology
  • Royal College of Nursing
  • Royal College of Paediatrics & Child Health
  • Royal College of Pathologists
  • Royal College of Physicians

Others

  • Department of Health
  • Welsh Assembly Government

General

  • British National Formulary
  • Commissioning Support Appraisals Service
  • Department of Health, Social Services and Public Safety for Northern Ireland
  • Healthcare improvement Scotland

Comparator manufacturer(s)

  • Abbott (adalimumab)
  • Pfizer/Wyeth (etanercept, methotrexate)
  • Schering-Plough (infliximab)
  • Swedish Orphan Biovitrum Ltd (anakinra)
  • Relevant research groups
  • Arthritis Research UK

Evidence Review Group

  • Kleijnen Systematic Reviews Ltd
  • National Coordinating Centre for Health Technology Assessment

Associated Guideline Groups

  • None

Top


 

Project history

Date Update
23 February 2010 Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations.  Therefore, we now anticipate that the appraisal will begin during late November 2010. The deadline for submissions is expected in approximately early February 2011.
28 January 2011 Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early February 2011. The deadline for submissions is expected in approximately early April 2011.
Top


 

Key documents

This page was last updated: 27 April 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.